ARCHIVED - Summative Evaluation of the Blood Safety Contribution Program - Final Report

Appendix B: Literature Reviewed

• L’Agence française de sécurité sanitaire des produits de santé (AFSSAPS). (2005). Haemovigilance in France: annual report (2004).
• Allain, J.P. (2003). Transfusion risks of yesterday and of today. Transfusion Clinique et Biologique, 10, 1-5.
• Amin, M., Wilson, K., Tinmouth, A., & Hébert, P. (2004). Does a perception of increased blood safety mean increased blood transfusion? An assessment of the risk compensation theory in Canada. BioMed Central Public Health, 4, 20.
• Andreu, G., Morel, P., Forestier, F, Debeir, J., Rebibo, D., Javier, G., & Hervé, P. (2002). Hemovigilance network in France: Organization and analysis of immediate transfusion  incident reports from 1994 to 1998. Transfusion, 42, 1356-1364.
• AuBuchon, J.P., & Whitaker, B.I. (2007). America finds hemovigilance! Transfusion, 47, 1937-1942.
• Bihl, F., Castelli,D., Marincola, F., Dodd, R., & Brander, C. (2007). Transfusion-transmitted  infections. Journal of Translational Medicine, 5, 1-11.
• Blue Ribbon Committee on Bloodborne Parasitic Diseases. (2002, September). Blue Ribbon Committee on Bloodborne Parasitic Diseases. Canada Communicable Disease Report.
• Brinkerhoff, J. (2002). Assessing and improving partnership relationships and outcomes: A proposed framework. Evaluation and Program Planning, 25, 215-231.
• Buehler, J.W. (1998). Surveillance. In K.J. Rothman, & S. Greenland. Modern epidemiology (2nd ed.). Pennsylvania: Lippencott-Raven.
• Busch, M.P., Kleinman, S.H., & Nemo, G.J. (2003). Current and emerging infectious risks of blood transfusions. Journal of the American Medical Association, 289, 959-962.
• Canadian Council for Donation and Transplantation (CCDT). Mohr, J. (2008). Surveillance of recipients of organ and tissue transplants.
• Centres for Disease Control and Prevention (CDC). (1999). An ounce of prevention: What are the returns? (2nd ed.). Georgia:  Department of Health and Human Services, CDC.
• Centres for Disease Control and Prevention (CDC). (1999). Impact of vaccines universally recommended for children – United States, 1990–1998. Morbidity and Mortality Weekly Report, 48, 243-248.
• Commission Directive 2005/62/EC 30 September 2005; implementing Directive2002/98/EC of the European Parliament and of the Council as regards traceability requirements and notification of serious adverse reactions and events. Official Journal of European Union 2005, 1/10/2005, L 256/32-40.
• Centres for Disease Control and Prevention (CDC). (2001). Updated guidelines for evaluating public health surveillance systems: Recommendations from the guidelines working group. Morbidity and Mortality Weekly Report, 50, No. RR-13.
• Commission of Inquiry on the Blood System in Canada (1997).Krever Commission Report. Retrieved May 20, 2008, from www.phac-aspc.gc.ca/hcai-iamss/tti-it/reports_e.html
• Commonwealth of Australia. (2004). Connection Government. Whole of Government Responses to Australia’s Priority Challenges, Good Practices Guides.
• Council of Europe Publishing. (2007). Guide to the preparation use and quality assurance of blood components: Recommendation No. R(95) 15 (13th ed.). Strasbourg, Cedex: Council of Europe.
• Davis, A., Mandal, R., Johnson, M., Makar, R., Stowell, C., & Dzik, S. (2008). A touch of TRALI. Transfusion, 48, 541-545.
• Directive 2002/98/EC of the European Parliament and of the Council. (2003). Setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC. Official Journal of the European Union, 311, 67-128.
• Dodd, R.Y., Notari, E.P., & Stramer, S.L. (2002). Current prevalence and incidence of infectious disease markers and estimated windowperiod risk in the American Red Cross blood donor population. Transfusion, 42, 975-979.
• Engelfriet, C.P., & Reesink, H.W. (1999). Haemovigilance systems. Vox Sanguinis, 77, 110-120.
• European Haemovigilance Network. Retrieved May 20, 2008, from http://www.ehn-org.net/
• Faber, J.C. (2000). L’hémovigilance en Europe. Transfusion Clinique et Biologique, 7, 5- 8.
• Faber, J.C. (2003). Hemovigilance: Definition and overview of current hemovigilance systems. Transfusion Alternatives in Transfusion Medicine, 5, 237-245.
• Faber, J.C. (2004). Worldwide overview of existing haemovigilance systems. Transfusion and Apheresis Science, 31, 99-110.
• Faber, J.C. (2006). European Haemovigilance Network: Organisation and Tasks. Transfusion Today, 66, 10-13.
• Gauvin, F., Lacroix, J., Robillard, P., Lapointe, H., & Hume, H. (2006). Acute transfusion reactions in the pediatric intensive care unit. Transfusion, 46, 1899-1908.
• Goldman, M., Webert, K.E., Arnold, D.M., Freedman, J., Hannon, J., & Blajchman, M.A. (2005). Proceedings of a concensus conference: Towards an understanding of TRALI. Transfusion Medicine Reviews, 19, 2-31.
• Gray, A., Jenkins, B., Leeuw, F., & Mayne, J. (2003). Collaboration in Public Services. Comparative Policy Analysis Volume X. New Brunswick (U.S.A.) and London (U.K.): Transaction Publishers.
• Health Surveillance Coordinating Committee (HSCC), Population and Public Health   Branch, & Health Canada. (2004). Framework and Tools for Evaluating Health Surveillance Systems (V 1.0).
• Heddell, G. (2007). Meeting the standards of the EU blood directive: Interview with Gerald Heddell by Barry Hill. The Biomedical Scientist, 12, 33: 29-32.
• Hinman, A.R., & Koplan, J.P. (1984). Pertussis and pertussis vaccine: Reanalysis of benefits, risks, and costs. Journal of the American Medical Association, 251, 3109–3113.
• Jorgensen, J., & Taaning, E. (2003). DART – A voluntary system of hemovigilance in Denmark. Transfusion Alternatives in Transfusion Medicine 5, 260-264.
• Krause, G. (2006). From evaluation to continuous quality assurance of surveillance systems. Eurosurveillance, 11, ii-657.
• Laperche, S. (2005). Blood safety and nucleic acid testing in Europe. Eurosurveillance, 10, 3-4.
• Le Drezen, L., Lepiouf, L., Léostic, C., Barra, J.A., & Le Niger, C. (2004). A quality program in haemovigilance: Evaluation of the blood transfusion chain. Transfusion Clinique et Biologique, 11, 138-145.
• Lozach, P., Vicariot., M., Le Niger, C., Pomey, M.P., Lejeune, B., Férec, C., Chaperon, J., & Salmi, L.R. (2001). Brest evaluation of the reporting system of transfusion reactions at Brest Univerisity Hospital. Transfusion Clinique et Biologique, 8, 343-349.
• Luban, N.L.C. (2005). Transfusion safety: Where are we today? Annals of the New York Academy of Sciences, 1054, 325-341.
• MacDonald, N. (2005). Transfusion and risk of infection in Canada: Update 2005. Canadian Journal of Infectious Diseases & Medical Microbiology, 16, 161-165.
• McClelland, B., & Contreras, M. (2005). Appropriateness and safety of blood transfusion. British Medical Journal, 330, 104-105.
• National Health Surveillance Network Working Groups, (1999). Proposal to develop a network for health surveillance in Canada.
• New Zealand Ministry of Social Policy. (2000). Models of community government partnerships     and their effectiveness in achieving welfare goals.
• Politis, C. (2005). The economics of blood. Transfusion Today, 65, 5-6.
• Public Health Agency of Canada. (2008). Creutzfeldt-Jakob Disease Surveillance, Retrieved May 20, 2008, from www.phac-aspc.gc.ca/hcai-iamss/cjd-mcj/index-eng.php
• Rebibo, D, Hauser, L., Slimani, A., Herve, P., & Audreu, G. (2003). The French haemovigilance system: organization and results for 2003. Transfusion and Apheresis Science, 31, 2, 145 -153.
• Robillard, E. (2006, September). The ISBT Working Part of Haemovigilance. Transfusion Today, 68, 4.
• Robillard, E., Chan, P. and Kleinman, S. (2004). Hemovigilance for the improvement of  blood safety. Transfusion and Apheresis Science, 31, 95-98.
• Robillard, P., Nawej, K.I., & Jochem, K. (2004). The Quebec hemovigilance system: Description and results from the first two years. Transfusion and Apheresis Science, 31, 2, 111-122.
• Robinson, E. (2007). The European union blood safety directive and its implications for blood services. Vox Sanguinis, 93, 122-130.
• Rouger, P., & Hergon, E. (1998). Contribution of haemovigilance to immunological safety of blood transfusions: Assessment after 3 years. Transfusion Clinique et Biologique, 5, 219-224.
• Serious Adverse Blood Reactions & Events (SABRE). Medicines and Healthcare Products Regulatory Agency (MHRA). (2005). SABRE – a user guide: UK blood safety and quality regulations 2005 – Implementation of the EU blood safety directive.
• Serious Hazards of Transfusion (SHOT). (2008, April). SHOT in 2008. SHOT 1(1). Retrieved May 20, 2008, from www.shotuk.org/newsletter.pdf
• Serious Hazards of Transfusion (SHOT).. Medicines and Healthcare Products Regulatory Agency (MHRA). (2005). UK blood safety and quality regulations 2005: Implementation of the EU blood safety directive – Background and guidance on reporting serious adverse events & serious adverse reactions.
• Stainsby, D., Jones, H., Asher, D., Atterbury, C., Boncinelli, A., Brant, L., Chapman, C.E., Davison, K., Gerrard, R., Gray, A., Knowles, S., Love, E.M., Milkins, C., Brian, D., McClelland L., Norfolk, D.R., Soldan, K., Taylor, C., Revill, J., Williamson, L.M., & Cohen, H. (2006). Serious hazards of transfusion: A decade of hemovigilance in the UK. Transfusion Medicine Reviews, 20, 273-282.
• Stainsby, D., Jones, H., Wells, A.W., Gibson, B., & Cohen, H. (2008). Adverse outcomes of blood transfusion in children: analysis of UK reports to the serious hazards of transfusion scheme 1996-2005. British Journal of haematology, 141, 73-79.
• Stainsby, D, Williamson L, Jones H, & Cohen H. (2004). Transfusion and Apheresis Science, 31, 2, 95-98.
• Taylor-Powell, E. (1999). Evaluating Collaboratives: Challenges and Practice. The Evaluation Exchange Volume V, no. 2/3.
• Teutsch, S.M., & Thacker, S.B. (1995). Planning a public health surveillance system. Epidemiological Bulletin: Pan American Health Organization, 16, 1-6.
• Thacker, S.B. (2000). Historical development. In S.M. Teutsch, & R.E. Churchill (Eds.), Principles and practice of public health surveillance (2nd ed.). New York, NY: Oxford University Press.
• Thacker, S.B., & Berkelman, R.L. (1988). Public health surveillance in the United States. Epidemiologic Reviews, 10, 164-190.
• Treasury Board of Canada Secretariat. (2007). Guide to the preparation of part III of the estimates: Reports on plans and priorities (RPP) and departmental performance reports (DPR). Treasury Board of Canada Secretariat. (2008). Guide to the preparation of part III of the estimates: Table 16 – Horizontal initiatives.
• Turner, G. (2007). Creutzfeldt-Jakob disease: an update. The Biomedical Scientist, 6, 437-439.
• UK Blood Transfusion Services (2005), Guidelines for the Blood Transfusion Services in the United Kingdom. London, UK: TSO.
• Vamvakas, E., Kleinman, S., Hume, H., & Sher, G. The development of West Nile virus safety policies by Canadian Blood Services: Guiding principles and a comparison between Canada and the United States. Transfusion Medicine Reviews, 20, 97-109.
• Van Hulst, M., De Wolf, J.T., Staginnus, U., Ruitenberg, E.J., & Postma, M.J. (2002). Pharmaco-economics of blood transfusion safety: Review of the available evidence. Vox Sanguinis, 83, 146-155.
• Verret, C., Mathoulin-Pélissier, Courbil, R., Perez, P., Destruel, F., Roubinet, F., Rech, H., Vidal, I., & Salmi, L.R. (1998). Evaluation of the system of traceability of the unstable blood products in Midday-Pyrenees area. Transfusion Clinique et Biologique, 5, 275-282.
• Williamson, L.M. (2002). Transfusion hazard reporting: Powerful data, but do we know how best to use it? Transfusion, 42, 1249-1252.
• Wilson, K., & Hebert, P.C. (2003). The challenge of an increasingly expensive blood system.Canadian Medical Association Journal , 168, 1149-1150.
• World Health Organization Geneva. (2001). Making surveillance work. Module 4: Data management.